Marshall Wace’s ClearPoint Neuro CLPT Stock Holding History

Marshall Wace’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-52,259	Closed	-$476K	–	3230
2026 Q1	$476K	Buy	+52,259	New	+$660K	﹤0.01%	2475
2025 Q2	–	Sell	-87,634	Closed	-$1.04M	–	2758
2025 Q1	$1.04M	Buy	87,634 +74,781	+582%	+$1.16M	﹤0.01%	1762
2024 Q4	$198K	Sell	12,853 -263,779	-95%	-$3.42M	﹤0.01%	2357
2024 Q3	$3.1M	Buy	276,632 +218,372	+375%	+$2.09M	﹤0.01%	1198
2024 Q2	$314K	Buy	58,260 +38,984	+202%	+$226K	﹤0.01%	2131
2024 Q1	$131K	Buy	+19,276	New	+$135K	﹤0.01%	2281
2023 Q3	–	Sell	-26,372	Closed	-$191K	–	2251
2023 Q2	$191K	Buy	+26,372	New	+$224K	﹤0.01%	2247
2023 Q1	–	Sell	-18,046	Closed	-$153K	–	2716
2022 Q4	$153K	Buy	+18,046	New	+$171K	﹤0.01%	2736
2022 Q2	–	Sell	-32,033	Closed	-$333K	–	3472
2022 Q1	$333K	Sell	32,033 -26,532	-45%	-$241K	﹤0.01%	2936
2021 Q4	$657K	Buy	+58,565	New	+$877K	﹤0.01%	2670
2021 Q3	–	Sell	-56,391	Closed	-$1.08M	–	3062
2021 Q2	$1.08M	Buy	+56,391	New	+$1.09M	﹤0.01%	1771

Other funds holding CLPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

CFM

Compass Financial Management Tampa, Florida $829M AUM

Marshall Wace's CLPT Position: Q2 2026 in Review

Marshall Wace sold out of ClearPoint Neuro (CLPT) in Q2 2026, closing a stake of 52,259 shares — an estimated $476K sold.

Marshall Wace first reported a position in CLPT in Q2 2021 and held it in 11 quarters. The position peaked at $3.1M in Q3 2024. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

Marshall Wace reported no remaining ClearPoint Neuro position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 52,259 ClearPoint Neuro shares in Q2 2026, an estimated $476K.
Marshall Wace first reported a position in ClearPoint Neuro in Q2 2021 and held it in 11 quarters.
Marshall Wace's ClearPoint Neuro position peaked at $3.1M in Q3 2024.
129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.